ENTRY       hsa05224                    Pathway
NAME        Breast cancer - Homo sapiens (human)
DESCRIPTION Breast cancer is the leading cause of cancer death among women worldwide. The vast majority of breast cancers are carcinomas that originate from cells lining the milk-forming ducts of the mammary gland. The molecular subtypes of breast cancer, which are based on the presence or absence of hormone receptors (estrogen and progesterone subtypes) and human epidermal growth factor receptor-2 (HER2), include: hormone receptor positive and HER2 negative (luminal A subtype), hormone receptor positive and HER2 positive (luminal B subtype), hormone receptor negative and HER2 positive (HER2 positive), and hormone receptor negative and HER2 negative (basal-like or triple-negative breast cancers (TNBCs)). Hormone receptor positive breast cancers are largely driven by the estrogen/ER pathway. In HER2 positive breast tumours, HER2 activates the PI3K/AKT and the RAS/RAF/MAPK pathways, and stimulate cell growth, survival and differentiation. In patients suffering from TNBC, the deregulation of various signalling pathways (Notch and Wnt/beta-catenin), EGFR protein have been confirmed. In the case of breast cancer only 8% of all cancers are hereditary, a phenomenon linked to genetic changes in BRCA1 or BRCA2. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers.
CLASS       Human Diseases; Cancers: Specific types
PATHWAY_MAP hsa05224  Breast cancer
NETWORK     nt06210  ERK signaling
            nt06214  PI3K signaling
            nt06215  WNT signaling
            nt06216  NOTCH signaling
            nt06227  NR signaling
            nt06230  Cell cycle G1/S
            nt06240  Transcription
            nt06260  Colorectal cancer
            nt06261  Gastric cancer
            nt06262  Pancreatic cancer
            nt06263  Hepatocellular carcinoma
            nt06265  Bladder cancer
            nt06266  Non-small cell lung cancer
            nt06267  Small cell lung cancer
            nt06268  Melanoma
            nt06269  Basal cell carcinoma
            nt06270  Breast cancer
            nt06271  Endometrial cancer
            nt06272  Prostate cancer
            nt06273  Glioma
            nt06274  Thyroid cancer
            nt06276  Chronic myeloid leukemia
  ELEMENT   N00020  Amplified FGFR to RAS-ERK signaling pathway
            N00022  ERBB2-overexpression to RAS-ERK signaling pathway
            N00034  ERBB2-overexpression to PI3K signaling pathway
            N00038  Amplified FGFR to PI3K signaling pathway
            N00041  EGFR-overexpression to RAS-ERK signaling pathway
            N00042  EGFR-overexpression to PI3K signaling pathway
            N00049  Mutation-activated PI3K to PI3K signaling pathway
            N00050  Amplified PI3K to PI3K signaling pathway
            N00052  Mutation-inactivated PTEN to PI3K signaling pathway
            N00059  FZD7-overexpression to Wnt signaling pathway
            N00060  LRP6-overexpression to Wnt signaling pathway
            N00087  NOTCH-overexpression to Notch signaling pathway
            N00115  Mutation-inactivated TP53 to transcription
            N00275  Amplified CCND1 to cell cycle G1/S
            N00287  ESR1-positive to nuclear-initiated estrogen signaling pathway
DISEASE     H00031  Breast cancer
DRUG        D00554  Ethinyl estradiol (USP)
            D00951  Medroxyprogesterone acetate (JP17/USP)
            D00966  Tamoxifen citrate (JP17/USP)
            D00967  Toremifene citrate (JAN/USAN)
            D01161  Fulvestrant (JAN/USAN/INN)
            D01602  Mepitiostane (JP17/INN)
            D02714  Everolimus (JAN/USAN/INN)
            D03257  Trastuzumab (USAN/INN)
            D04024  Lapatinib ditosylate (USAN)
            D05446  Pertuzumab (USAN/INN)
            D08108  Lapatinib (INN)
            D08950  Neratinib (USAN/INN)
            D09980  Trastuzumab emtansine (USAN/INN)
            D10372  Palbociclib (JAN/USAN)
            D10688  Abemaciclib (JAN/USAN)
            D10898  Neratinib maleate
            D10979  Ribociclib succinate (USAN)
ORGANISM    Homo sapiens (human) [GN:hsa]
GENE        2099  ESR1; estrogen receptor 1 [KO:K08550]
            2100  ESR2; estrogen receptor 2 [KO:K08551]
            8648  NCOA1; nuclear receptor coactivator 1 [KO:K09101] [EC:2.3.1.48]
            8202  NCOA3; nuclear receptor coactivator 3 [KO:K11256] [EC:2.3.1.48]
            2353  FOS; Fos proto-oncogene, AP-1 transcription factor subunit [KO:K04379]
            3725  JUN; Jun proto-oncogene, AP-1 transcription factor subunit [KO:K04448]
            6667  SP1; Sp1 transcription factor [KO:K04684]
            595  CCND1; cyclin D1 [KO:K04503]
            4609  MYC; MYC proto-oncogene, bHLH transcription factor [KO:K04377]
            5241  PGR; progesterone receptor [KO:K08556]
            7471  WNT1; Wnt family member 1 [KO:K03209]
            54361  WNT4; Wnt family member 4 [KO:K00408]
            8600  TNFSF11; TNF superfamily member 11 [KO:K05473]
            2064  ERBB2; erb-b2 receptor tyrosine kinase 2 [KO:K05083] [EC:2.7.10.1]
            2246  FGF1; fibroblast growth factor 1 [KO:K18496]
            2247  FGF2; fibroblast growth factor 2 [KO:K18497]
            2248  FGF3; fibroblast growth factor 3 [KO:K04358]
            2249  FGF4; fibroblast growth factor 4 [KO:K04358]
            8822  FGF17; fibroblast growth factor 17 [KO:K04358]
            2251  FGF6; fibroblast growth factor 6 [KO:K04358]
            2252  FGF7; fibroblast growth factor 7 [KO:K04358]
            2253  FGF8; fibroblast growth factor 8 [KO:K04358]
            2254  FGF9; fibroblast growth factor 9 [KO:K04358]
            2255  FGF10; fibroblast growth factor 10 [KO:K04358]
            8823  FGF16; fibroblast growth factor 16 [KO:K04358]
            2250  FGF5; fibroblast growth factor 5 [KO:K04358]
            8817  FGF18; fibroblast growth factor 18 [KO:K04358]
            26281  FGF20; fibroblast growth factor 20 [KO:K04358]
            27006  FGF22; fibroblast growth factor 22 [KO:K04358]
            9965  FGF19; fibroblast growth factor 19 [KO:K22603]
            26291  FGF21; fibroblast growth factor 21 [KO:K22429]
            8074  FGF23; fibroblast growth factor 23 [KO:K22428]
            2260  FGFR1; fibroblast growth factor receptor 1 [KO:K04362] [EC:2.7.10.1]
            3479  IGF1; insulin like growth factor 1 [KO:K05459]
            3480  IGF1R; insulin like growth factor 1 receptor [KO:K05087] [EC:2.7.10.1]
            1950  EGF; epidermal growth factor [KO:K04357]
            1956  EGFR; epidermal growth factor receptor [KO:K04361] [EC:2.7.10.1]
            3815  KIT; KIT proto-oncogene, receptor tyrosine kinase [KO:K05091] [EC:2.7.10.1]
            6464  SHC1; SHC adaptor protein 1 [KO:K06279]
            25759  SHC2; SHC adaptor protein 2 [KO:K17447]
            53358  SHC3; SHC adaptor protein 3 [KO:K17448]
            399694  SHC4; SHC adaptor protein 4 [KO:K17449]
            2885  GRB2; growth factor receptor bound protein 2 [KO:K04364]
            6654  SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 [KO:K03099]
            6655  SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 [KO:K03099]
            3265  HRAS; HRas proto-oncogene, GTPase [KO:K02833]
            3845  KRAS; KRAS proto-oncogene, GTPase [KO:K07827]
            4893  NRAS; NRAS proto-oncogene, GTPase [KO:K07828]
            369  ARAF; A-Raf proto-oncogene, serine/threonine kinase [KO:K08845] [EC:2.7.11.1]
            673  BRAF; B-Raf proto-oncogene, serine/threonine kinase [KO:K04365] [EC:2.7.11.1]
            5894  RAF1; Raf-1 proto-oncogene, serine/threonine kinase [KO:K04366] [EC:2.7.11.1]
            5604  MAP2K1; mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
            5605  MAP2K2; mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
            5594  MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
            5595  MAPK3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
            5290  PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [KO:K00922] [EC:2.7.1.153]
            5293  PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922] [EC:2.7.1.153]
            5291  PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta [KO:K00922] [EC:2.7.1.153]
            5295  PIK3R1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649]
            5296  PIK3R2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649]
            8503  PIK3R3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649]
            5728  PTEN; phosphatase and tensin homolog [KO:K01110] [EC:3.1.3.67 3.1.3.48 3.1.3.16]
            207  AKT1; AKT serine/threonine kinase 1 [KO:K04456] [EC:2.7.11.1]
            208  AKT2; AKT serine/threonine kinase 2 [KO:K04456] [EC:2.7.11.1]
            10000  AKT3; AKT serine/threonine kinase 3 [KO:K04456] [EC:2.7.11.1]
            2475  MTOR; mechanistic target of rapamycin kinase [KO:K07203] [EC:2.7.11.1]
            6198  RPS6KB1; ribosomal protein S6 kinase B1 [KO:K04688] [EC:2.7.11.1]
            6199  RPS6KB2; ribosomal protein S6 kinase B2 [KO:K04688] [EC:2.7.11.1]
            182  JAG1; jagged canonical Notch ligand 1 [KO:K06052]
            3714  JAG2; jagged canonical Notch ligand 2 [KO:K21635]
            10683  DLL3; delta like canonical Notch ligand 3 [KO:K06051]
            28514  DLL1; delta like canonical Notch ligand 1 [KO:K06051]
            54567  DLL4; delta like canonical Notch ligand 4 [KO:K06051]
            4851  NOTCH1; notch receptor 1 [KO:K02599]
            4853  NOTCH2; notch receptor 2 [KO:K20994]
            4854  NOTCH3; notch receptor 3 [KO:K20995]
            4855  NOTCH4; notch receptor 4 [KO:K20996]
            3280  HES1; hes family bHLH transcription factor 1 [KO:K06054]
            388585  HES5; hes family bHLH transcription factor 5 [KO:K06055]
            26508  HEYL; hes related family bHLH transcription factor with YRPW motif like [KO:K09091]
            23462  HEY1; hes related family bHLH transcription factor with YRPW motif 1 [KO:K09091]
            23493  HEY2; hes related family bHLH transcription factor with YRPW motif 2 [KO:K09091]
            2324  FLT4; fms related tyrosine kinase 4 [KO:K05097] [EC:2.7.10.1]
            1026  CDKN1A; cyclin dependent kinase inhibitor 1A [KO:K06625]
            4791  NFKB2; nuclear factor kappa B subunit 2 [KO:K04469]
            7472  WNT2; Wnt family member 2 [KO:K00182]
            7482  WNT2B; Wnt family member 2B [KO:K00182]
            7473  WNT3; Wnt family member 3 [KO:K00312]
            89780  WNT3A; Wnt family member 3A [KO:K00312]
            7474  WNT5A; Wnt family member 5A [KO:K00444]
            81029  WNT5B; Wnt family member 5B [KO:K00444]
            7475  WNT6; Wnt family member 6 [KO:K00445]
            7476  WNT7A; Wnt family member 7A [KO:K00572]
            7477  WNT7B; Wnt family member 7B [KO:K00572]
            7478  WNT8A; Wnt family member 8A [KO:K00714]
            7479  WNT8B; Wnt family member 8B [KO:K00714]
            7483  WNT9A; Wnt family member 9A [KO:K01064]
            7484  WNT9B; Wnt family member 9B [KO:K01064]
            7480  WNT10B; Wnt family member 10B [KO:K01357]
            80326  WNT10A; Wnt family member 10A [KO:K01357]
            7481  WNT11; Wnt family member 11 [KO:K01384]
            51384  WNT16; Wnt family member 16 [KO:K01558]
            8321  FZD1; frizzled class receptor 1 [KO:K02432]
            8324  FZD7; frizzled class receptor 7 [KO:K02432]
            2535  FZD2; frizzled class receptor 2 [KO:K02235]
            7976  FZD3; frizzled class receptor 3 [KO:K02329]
            8322  FZD4; frizzled class receptor 4 [KO:K02354]
            7855  FZD5; frizzled class receptor 5 [KO:K02375]
            8325  FZD8; frizzled class receptor 8 [KO:K02375]
            8323  FZD6; frizzled class receptor 6 [KO:K02376]
            11211  FZD10; frizzled class receptor 10 [KO:K02842]
            8326  FZD9; frizzled class receptor 9 [KO:K02842]
            4041  LRP5; LDL receptor related protein 5 [KO:K03068]
            4040  LRP6; LDL receptor related protein 6 [KO:K03068]
            1857  DVL3; dishevelled segment polarity protein 3 [KO:K02353]
            1856  DVL2; dishevelled segment polarity protein 2 [KO:K02353]
            1855  DVL1; dishevelled segment polarity protein 1 [KO:K02353]
            10023  FRAT1; FRAT regulator of WNT signaling pathway 1 [KO:K03069]
            23401  FRAT2; FRAT regulator of WNT signaling pathway 2 [KO:K03096]
            2932  GSK3B; glycogen synthase kinase 3 beta [KO:K03083] [EC:2.7.11.26]
            8312  AXIN1; axin 1 [KO:K02157]
            8313  AXIN2; axin 2 [KO:K04385]
            324  APC; APC regulator of WNT signaling pathway [KO:K02085]
            10297  APC2; APC regulator of WNT signaling pathway 2 [KO:K02085]
            1499  CTNNB1; catenin beta 1 [KO:K02105]
            122011  CSNK1A1L; casein kinase 1 alpha 1 like [KO:K08957] [EC:2.7.11.1]
            1452  CSNK1A1; casein kinase 1 alpha 1 [KO:K08957] [EC:2.7.11.1]
            6932  TCF7; transcription factor 7 [KO:K02620]
            83439  TCF7L1; transcription factor 7 like 1 [KO:K04490]
            6934  TCF7L2; transcription factor 7 like 2 [KO:K04491]
            51176  LEF1; lymphoid enhancer binding factor 1 [KO:K04492]
            7157  TP53; tumor protein p53 [KO:K04451]
            1647  GADD45A; growth arrest and DNA damage inducible alpha [KO:K04402]
            4616  GADD45B; growth arrest and DNA damage inducible beta [KO:K04402]
            10912  GADD45G; growth arrest and DNA damage inducible gamma [KO:K04402]
            581  BAX; BCL2 associated X, apoptosis regulator [KO:K02159]
            578  BAK1; BCL2 antagonist/killer 1 [KO:K14021]
            1643  DDB2; damage specific DNA binding protein 2 [KO:K10140]
            51426  POLK; DNA polymerase kappa [KO:K03511] [EC:2.7.7.7]
            1019  CDK4; cyclin dependent kinase 4 [KO:K02089] [EC:2.7.11.22]
            1021  CDK6; cyclin dependent kinase 6 [KO:K02091] [EC:2.7.11.22]
            5925  RB1; RB transcriptional corepressor 1 [KO:K06618]
            1869  E2F1; E2F transcription factor 1 [KO:K17454]
            1870  E2F2; E2F transcription factor 2 [KO:K09389]
            1871  E2F3; E2F transcription factor 3 [KO:K06620]
            672  BRCA1; BRCA1 DNA repair associated [KO:K10605] [EC:2.3.2.27]
            675  BRCA2; BRCA2 DNA repair associated [KO:K08775]
COMPOUND    C00410  Progesterone
            C00951  Estradiol-17beta
            C05981  Phosphatidylinositol-3,4,5-trisphosphate
REFERENCE   PMID:24649067
  AUTHORS   Zhang MH, Man HT, Zhao XD, Dong N, Ma SL
  TITLE     Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).
  JOURNAL   Biomed Rep 2:41-52 (2014)
            DOI:10.3892/br.2013.187
REFERENCE   PMID:27390604
  AUTHORS   Dai X, Xiang L, Li T, Bai Z
  TITLE     Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.
  JOURNAL   J Cancer 7:1281-94 (2016)
            DOI:10.7150/jca.13141
REFERENCE   PMID:20436504
  AUTHORS   Schnitt SJ
  TITLE     Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy.
  JOURNAL   Mod Pathol 23 Suppl 2:S60-4 (2010)
            DOI:10.1038/modpathol.2010.33
REFERENCE   PMID:23000897
  AUTHORS   
  TITLE     Comprehensive molecular portraits of human breast tumours.
  JOURNAL   Nature 490:61-70 (2012)
            DOI:10.1038/nature11412
REFERENCE   PMID:22178455
  AUTHORS   Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A
  TITLE     Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.
  JOURNAL   Cancer Treat Rev 38:698-707 (2012)
            DOI:10.1016/j.ctrv.2011.11.005
REFERENCE   
  AUTHORS   Karamouzis MV, Papavassiliou KA, Adamopoulos C, Papavassiliou AG.
  TITLE     Targeting androgen/estrogen receptors crosstalk in cancer
  JOURNAL   Trends in Cancer 2(1):35-48 (2016)
            DOI:10.1016/j.trecan.2015.12.001
REFERENCE   
  AUTHORS   Sharp A, Harper-Wynne C.
  TITLE     Treatment of advanced breast cancer (ABC): the expanding landscape of targeted therapies
  JOURNAL   J Cancer Biol Res 2(1):1036 (2014)
REFERENCE   PMID:24596345
  AUTHORS   Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, Sarkar S
  TITLE     Genetic and epigenetic aspects of breast cancer progression and therapy.
  JOURNAL   Anticancer Res 34:1071-7 (2014)
REFERENCE   PMID:23988612
  AUTHORS   Mohamed A, Krajewski K, Cakar B, Ma CX
  TITLE     Targeted therapy for breast cancer.
  JOURNAL   Am J Pathol 183:1096-112 (2013)
            DOI:10.1016/j.ajpath.2013.07.005
REFERENCE   PMID:22722193
  AUTHORS   Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER
  TITLE     Whole-genome analysis informs breast cancer response to aromatase inhibition.
  JOURNAL   Nature 486:353-60 (2012)
            DOI:10.1038/nature11143
REFERENCE   PMID:25907219
  AUTHORS   Ma CX, Reinert T, Chmielewska I, Ellis MJ
  TITLE     Mechanisms of aromatase inhibitor resistance.
  JOURNAL   Nat Rev Cancer 15:261-75 (2015)
            DOI:10.1038/nrc3920
REFERENCE   PMID:16113099
  AUTHORS   Butt AJ, McNeil CM, Musgrove EA, Sutherland RL
  TITLE     Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E.
  JOURNAL   Endocr Relat Cancer 12 Suppl 1:S47-59 (2005)
            DOI:10.1677/erc.1.00993
REFERENCE   PMID:24111892
  AUTHORS   Dasgupta S, Lonard DM, O'Malley BW
  TITLE     Nuclear receptor coactivators: master regulators of human health and disease.
  JOURNAL   Annu Rev Med 65:279-92 (2014)
            DOI:10.1146/annurev-med-051812-145316
REFERENCE   PMID:23702927
  AUTHORS   Brisken C
  TITLE     Progesterone signalling in breast cancer: a neglected hormone coming into the limelight.
  JOURNAL   Nat Rev Cancer 13:385-96 (2013)
            DOI:10.1038/nrc3518
REFERENCE   PMID:20087430
  AUTHORS   Scarpin KM, Graham JD, Mote PA, Clarke CL
  TITLE     Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression.
  JOURNAL   Nucl Recept Signal 7:e009 (2009)
            DOI:10.1621/nrs.07009
REFERENCE   PMID:24291072
  AUTHORS   Knutson TP, Lange CA
  TITLE     Tracking progesterone receptor-mediated actions in breast cancer.
  JOURNAL   Pharmacol Ther 142:114-25 (2014)
            DOI:10.1016/j.pharmthera.2013.11.010
REFERENCE   PMID:25544707
  AUTHORS   Dittrich A, Gautrey H, Browell D, Tyson-Capper A
  TITLE     The HER2 Signaling Network in Breast Cancer--Like a Spider in its Web.
  JOURNAL   J Mammary Gland Biol Neoplasia 19:253-70 (2014)
            DOI:10.1007/s10911-014-9329-5
REFERENCE   PMID:21965336
  AUTHORS   Higgins MJ, Baselga J
  TITLE     Targeted therapies for breast cancer.
  JOURNAL   J Clin Invest 121:3797-803 (2011)
            DOI:10.1172/JCI57152
REFERENCE   PMID:26028978
  AUTHORS   Mukohara T
  TITLE     PI3K mutations in breast cancer: prognostic and therapeutic implications.
  JOURNAL   Breast Cancer (Dove Med Press) 7:111-23 (2015)
            DOI:10.2147/BCTT.S60696
REFERENCE   PMID:19088017
  AUTHORS   Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA
  TITLE     Triple-negative breast cancer: risk factors to potential targets.
  JOURNAL   Clin Cancer Res 14:8010-8 (2008)
            DOI:10.1158/1078-0432.CCR-08-1208
REFERENCE   PMID:21898546
  AUTHORS   King TD, Suto MJ, Li Y
  TITLE     The Wnt/beta-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer.
  JOURNAL   J Cell Biochem 113:13-8 (2012)
            DOI:10.1002/jcb.23350
REFERENCE   PMID:11737884
  AUTHORS   Brown AM
  TITLE     Wnt signaling in breast cancer: have we come full circle?
  JOURNAL   Breast Cancer Res 3:351-5 (2001)
            DOI:10.1186/bcr321
REFERENCE   PMID:21076461
  AUTHORS   Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, Natrajan R, Reis-Filho JS
  TITLE     beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation.
  JOURNAL   Mod Pathol 24:209-31 (2011)
            DOI:10.1038/modpathol.2010.205
REFERENCE   PMID:20971825
  AUTHORS   Al-Hussaini H, Subramanyam D, Reedijk M, Sridhar SS
  TITLE     Notch signaling pathway as a therapeutic target in breast cancer.
  JOURNAL   Mol Cancer Ther 10:9-15 (2011)
            DOI:10.1158/1535-7163.MCT-10-0677
REFERENCE   PMID:26968398
  AUTHORS   Rangel MC, Bertolette D, Castro NP, Klauzinska M, Cuttitta F, Salomon DS
  TITLE     Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer.
  JOURNAL   Breast Cancer Res Treat 156:211-26 (2016)
            DOI:10.1007/s10549-016-3746-7
REFERENCE   PMID:26040571
  AUTHORS   Jamdade VS, Sethi N, Mundhe NA, Kumar P, Lahkar M, Sinha N
  TITLE     Therapeutic targets of triple-negative breast cancer: a review.
  JOURNAL   Br J Pharmacol 172:4228-37 (2015)
            DOI:10.1111/bph.13211
REFERENCE   PMID:23196196
  AUTHORS   Karamboulas C, Ailles L
  TITLE     Developmental signaling pathways in cancer stem cells of solid tumors.
  JOURNAL   Biochim Biophys Acta 1830:2481-95 (2013)
            DOI:10.1016/j.bbagen.2012.11.008
REFERENCE   PMID:23881035
  AUTHORS   Ignatiadis M, Sotiriou C
  TITLE     Luminal breast cancer: from biology to treatment.
  JOURNAL   Nat Rev Clin Oncol 10:494-506 (2013)
            DOI:10.1038/nrclinonc.2013.124
REFERENCE   PMID:25013431
  AUTHORS   Shin SJ, Gong G, Lee HJ, Kang J, Bae YK, Lee A, Cho EY, Lee JS, Suh KS, Lee DW, Jung WH
  TITLE     Positive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status and a favorable prognosis in breast cancer.
  JOURNAL   J Breast Cancer 17:113-20 (2014)
            DOI:10.4048/jbc.2014.17.2.113
REFERENCE   PMID:11879567
  AUTHORS   Gasco M, Shami S, Crook T
  TITLE     The p53 pathway in breast cancer.
  JOURNAL   Breast Cancer Res 4:70-6 (2002)
            DOI:10.1186/bcr426
REFERENCE   PMID:15343273
  AUTHORS   Narod SA, Foulkes WD
  TITLE     BRCA1 and BRCA2: 1994 and beyond.
  JOURNAL   Nat Rev Cancer 4:665-76 (2004)
            DOI:10.1038/nrc1431
KO_PATHWAY  ko05224
///
